Drug Trial News

RSS

BioCryst starts BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX4161 in healthy volunteers.

25 Mar 2013

Newly discovered molecule could form the basis of anti-malaria drugs

An international study, involving researchers from Griffith University's Eskitis Institute, has discovered a molecule which could form the basis of powerful new anti-malaria drugs.

25 Mar 2013

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for Affinium's first-in-class, novel antibiotic targeted against bacterial fatty acid biosynthesis inhibition (FabI inhibitors).

21 Mar 2013

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.

21 Mar 2013

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy, announced today that it is developing a SARM drug candidate obtained from Belgium-based Galapagos NV.

21 Mar 2013

New imaging agent detects, maps cancers that have reached lymph nodes

Researchers at the University of California, San Diego School of Medicine have shown that a new imaging dye, designed and developed at UC San Diego Moores Cancer Center, is an effective agent in detecting and mapping cancers that have reached the lymph nodes.

21 Mar 2013

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides.

21 Mar 2013

Study: Drug normally used to treat severe bronchial asthma beneficial for chronic urticaria sufferers

An international study involving dermatologists from the Hospital del Mar and Spanish subjects has concluded that a drug normally used to treat severe bronchial asthma caused by allergies (Omalizumab) rapidly eliminates the symptoms of spontaneous chronic urticaria, a development that it is expected will significantly improve the quality of life of chronic urticaria sufferers.

21 Mar 2013

Hepatitis C and HIV co-infection treatment: an interview with Prof Boecher, Boehringer Ingelheim

Chronic hepatitis C infection is one of the most frequent chronic infectious diseases worldwide. The WHO estimates that 150 million people worldwide are chronically infected with the hepatitis C virus (HCV).

20 Mar 2013

Mozambique completes first HIV vaccine clinical trial

Last week, "researchers at Mozambique's Polana Cancio Centre for Research and Public Health completed a trial evaluating the safety of an HIV vaccine candidate," the country's "first HIV vaccine trial," and it "is set to embark on a second, a demonstration of the country's increased HIV research capacity," PlusNews reports.

20 Mar 2013

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

19 Mar 2013

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor, or TKI, that is being investigated for use in patients with advanced renal cell carcinoma (RCC), or kidney cancer.

19 Mar 2013

University of Nottingham to study use of tranexamic acid in people with intracerebral haemorrhage

Scientists in Nottingham are leading an international study to investigate the effectiveness of a new treatment on a devastating type of stroke.

19 Mar 2013

R-Tech Ueno enrolls retinitis pigmentosa patients in Phase 3 clinical study of UF-021 ophthalmic solution

R-Tech Ueno is pleased to announce the start of the patient enrollment of a Phase 3 clinical study with Unoprostone (development code UF-021) ophthalmic solution that are being developed in our company for the treatment of retinitis pigmentosa.

18 Mar 2013

Abiraterone's anti-androgenic properties may stop tumor growth of CRPC, says prize-winning Dutch study

As part of an EU-supported IMI-PREDECT consortium, a Dutch study showed that anti-androgenic properties of the drug abiraterone may provide an additional mechanism of action in blocking tumour growth of castration resistant prostate cancer (CRPC).

16 Mar 2013

Diffusion Pharmaceuticals enrolls patients with primary brain cancer in Phase II clinical trial of TSC

Diffusion Pharmaceuticals LLC today announced completion of enrollment in a Phase II clinical trial of trans sodium crocetinate, its lead compound for the treatment of cancer.

15 Mar 2013

Results from GTx's Phase 2 clinical trial of enobosarm published online

GTx, Inc. today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition the results from GTx's randomized, double-blind, placebo-controlled Phase 2 clinical trial of enobosarm to assess its effects on muscle wasting and physical function in patients with cancer.

15 Mar 2013

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

...

14 Mar 2013

Steroids used for treating TB may reduce death rates from all types of TB

The routine use of steroids to treat tuberculosis may help reduce deaths from all types of the disease, according to a new review of existing research.

14 Mar 2013

ASTRONAUT trial finds no beneficial effects of aliskiren in recently hospitalized heart failure patients

Despite high hopes that a blood pressure-lowering medication called aliskiren would help people following hospitalization for heart failure, no beneficial effects were found, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Drug Trial News

BioCryst starts BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

Newly discovered molecule could form the basis of anti-malaria drugs

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

New imaging agent detects, maps cancers that have reached lymph nodes

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Study: Drug normally used to treat severe bronchial asthma beneficial for chronic urticaria sufferers

Hepatitis C and HIV co-infection treatment: an interview with Prof Boecher, Boehringer Ingelheim

Mozambique completes first HIV vaccine clinical trial

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

University of Nottingham to study use of tranexamic acid in people with intracerebral haemorrhage

R-Tech Ueno enrolls retinitis pigmentosa patients in Phase 3 clinical study of UF-021 ophthalmic solution

Abiraterone's anti-androgenic properties may stop tumor growth of CRPC, says prize-winning Dutch study

Diffusion Pharmaceuticals enrolls patients with primary brain cancer in Phase II clinical trial of TSC

Results from GTx's Phase 2 clinical trial of enobosarm published online

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

Steroids used for treating TB may reduce death rates from all types of TB

ASTRONAUT trial finds no beneficial effects of aliskiren in recently hospitalized heart failure patients

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News